Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 21 Jul 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episode…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information
%3A%20Don't%20ignore%20suspected%20side%20effects%2C%20report%20them!%20Updates%20to%20the%20Yellow%20Card%20website%20and%20app/og.png)
Professional
#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app
The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and.
by Medicines and Healthcare products Regulatory Agency (MHRA)

Professional
Phaeochromocytoma
Wha... A phaeochromocytoma (PCC) is a rare tumour that secretes catecholamines. It is derived from chromaffin cells, usually in the adrenal medulla; however, occasionally extra-adrenal phaeochromocytomas or paragangliomas (PGLs) occur. Risk factors 'Phaeochromocytoma crisis', presents with severe hypertension, circulatory failure and shock, with.
by Dr Colin Tidy, MRCGP

Professional
The patient with newly diagnosed diabetes
Send urine for albumin:creatinine... Check renal function and electrolytes. Also check baseline LFTs (fatty liver is more common in people with diabetes). Consider whether there may be an underlying disorder causing or associated with diabetes - eg, pancreatitis Acute pancreatitis , Cushing's syndrome Cushing's syndrome , phaeochromocytoma.
by Dr Hayley Willacy, FRCGP

Professional
Influenza vaccination
Not to be confused with the Haemophilius influenzae Haemophilus influenzae vaccine. Influenza Influenza (flu) is a major cause of morbidity and mortality each year in the UK. Admissions to hospital in the UK tend to peak between December and February with the highest numbers of admissions with proven influenza (both to hospital and to intensive.
by Dr Philippa Vincent, MRCGP
%20-%20QOF%20indicator/og.png)
Professional
Hypertension (HYP) - QOF indicator
Hypertension indicators for 2026/27 The hypertension area of QOF assesses blood pressure control using age-specific targets, with equivalent home readings accepted. For 2026/27, HYP010 and HYP011 replace HYP008 and HYP009 respectively; both exclude patients with moderate or severe frailty to support individually tailored management. Ongoing.
by Patient infomatics team

Professional
Filters should be used during the administration of Parenteral Nutrition for patients in all care settings
...tion of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcomeRead the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices..
by Medicines and Healthcare products Regulatory Agency (MHRA)
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
21 Jul 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- NewClass 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45
- Class 2 Medicines Recall: Baxter Healthcare Limited, Compound Sodium Lactate Solution for Infusion BP (Hartmann's Solution for infusion) in Viaflo 1000ml, EL(25)A/46
- Class 2 Medicines Recall: Beckton Dickson UK Ltd, ChloraPrep 1mL applicator, EL(26)A/34
- Class 2 Medicines Recall: Bio Products Laboratory Limited, Rabies, Human normal Immunoglobulin 500IU solution for Injection, EL(26)A/18
- Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 10mg capsules, EL(26)A/19
- Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
- NewDuvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
- Field Safety Notices: 1 May 2026
- Field Safety Notices: 1 to 5 December 2025
- Field Safety Notices: 3 to 7 November 2025
- Field Safety Notices: 09-13 February 2026
- Field Safety Notices: 14 to 18 September 2026
- Field Safety Notices: 15 to 19 September 2025
- Field Safety Notices: 18 -22 May 2026
- Field Safety Notices: 20 to 24 October 2025
- Field Safety Notices: 22 to 26 June 2026
- Isotretinoin – updates to prescribing guidance and survey of services
- MHRA Safety Roundup: October 2025
- National Patient Safety Alert: Patient hoists and slings (all types): risk of death and serious harm from falls (NatPSA/2026/005/MHRA)
- Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013


